How Boehringer, Lilly Are Taming The GenAI Dragon For Regulatory, Commercial Content
Open AI's GPT-4 A Hit Among Users
Heads of AI, global commercial services and human pharma services at Boehringer and Eli Lilly discuss at a recent summit ways to use generative AI like ChatGPT for commercial and regulatory content while tackling challenges like data protection, hallucination and CXO buy-in
![Generative AI ChatGPT](https://insights.citeline.com/resizer/v2/XWCGKZYHEJNJRPTOQ5QGJ57LKE.jpg?smart=true&auth=b801c13d2d7705a6604049968b4f585fa10a56178cb8bf1e9b2e1113140268b7&width=700&height=394)